Business Wire08.05.20
BioMarker Strategies LLC announced the promotion of Greg Bertenshaw. Ph.D., to the position of chief operating and science officer. Dr. Bertenshaw, formerly Vice President, Research & Development, will continue to report directly to Jerry Parrott, president and CEO.
Dr. Bertenshaw joined BioMarker Strategies as a senior scientist in December 2011 and was promoted to director, Research & Development, in December 2012. Parrott joined BioMarker Strategies in October 2013 and promoted Dr. Bertenshaw to vice president, Research & Development, less than three months later.
Since the end of 2012, Dr. Bertenshaw has been responsible for development of the company’s core technologies, the SnapPath Cancer Diagnostics System and PathMAP Functional Signaling Profiles. He has also been responsible for working with DLA Piper to protect the company’s intellectual property on a global basis, including patents and trademarks.
Mr. Parrott said, “All of the patents granted to BioMarker Strategies around the world have been granted since I joined BioMarker Strategies as CEO in October 2013. My personal responsibility for this achievement rests on one decision. That was the decision to promote Greg Bertenshaw to vice president three months after joining the company. Greg is also principal investigator on all of the National Cancer Institute grants and contracts awarded to our company since the beginning of 2013. This includes the $1.5 Phase II Small Business Innovation Research contract we announced in January 2020, which supports continued development of our PathMAP Immunotherapy test to predict response to PD-1/PDL1 targeted immune checkpoint inhibitors, for individual patients with non-small lung cancer.”
The $8.3 million in nondilutive funding that BioMarker Strategies has received from NCI has provided important validation for the company’s proprietary ex vivo cancer diagnostics technology, and has also played a major role financially.
Prior to joining Human Genome Sciences, Dr. Bertenshaw served as director, New Technology, with Correlogic Systems Inc., from 2006-2011, and with Clearant Inc., from 2002-2006 as a scientist and subsequently as director of Science.
Dr. Bertenshaw earned a Ph.D. in biochemistry and molecular biology from Pennsylvania State University College of Medicine, and a bachelor of science degree in biochemistry from the University of Manchester, Manchester, United Kingdom.
Dr. Bertenshaw joined BioMarker Strategies as a senior scientist in December 2011 and was promoted to director, Research & Development, in December 2012. Parrott joined BioMarker Strategies in October 2013 and promoted Dr. Bertenshaw to vice president, Research & Development, less than three months later.
Since the end of 2012, Dr. Bertenshaw has been responsible for development of the company’s core technologies, the SnapPath Cancer Diagnostics System and PathMAP Functional Signaling Profiles. He has also been responsible for working with DLA Piper to protect the company’s intellectual property on a global basis, including patents and trademarks.
Mr. Parrott said, “All of the patents granted to BioMarker Strategies around the world have been granted since I joined BioMarker Strategies as CEO in October 2013. My personal responsibility for this achievement rests on one decision. That was the decision to promote Greg Bertenshaw to vice president three months after joining the company. Greg is also principal investigator on all of the National Cancer Institute grants and contracts awarded to our company since the beginning of 2013. This includes the $1.5 Phase II Small Business Innovation Research contract we announced in January 2020, which supports continued development of our PathMAP Immunotherapy test to predict response to PD-1/PDL1 targeted immune checkpoint inhibitors, for individual patients with non-small lung cancer.”
The $8.3 million in nondilutive funding that BioMarker Strategies has received from NCI has provided important validation for the company’s proprietary ex vivo cancer diagnostics technology, and has also played a major role financially.
Prior to joining Human Genome Sciences, Dr. Bertenshaw served as director, New Technology, with Correlogic Systems Inc., from 2006-2011, and with Clearant Inc., from 2002-2006 as a scientist and subsequently as director of Science.
Dr. Bertenshaw earned a Ph.D. in biochemistry and molecular biology from Pennsylvania State University College of Medicine, and a bachelor of science degree in biochemistry from the University of Manchester, Manchester, United Kingdom.